Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
In the ACACIA-HCM trial, aficamten demonstrated a statistically significant improvement over placebo in both KCCQ-CSS (P =.021) and pVO2 (P =.003) at 36 weeks, with no new safety signals observed.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Cytokinetics' cardiac myosin inhibitor Myqorzo has succeeded where first-to-market Camzyos from Bristol Myers Squibb failed, hitting the mark in a phase 3 trial in non-obstructive hypertrophic ...
Nick is a freelance writer from Chicago, IL, with a BA in Creative Writing from the University of Illinois at Urbana-Champaign. His lifelong belief in the artistic power of video games led him to ...
This page is now closed, but a summary of the game is available below, and you can click here for our full match report. Thanks for joining us at Al Jazeera Sport. Defending champions Paris ...
Cytokinetics, Incorporated's (CYTK) shares surged 40.4% on Sept. 2, driven by positive results from a phase III study on cardiovascular candidate aficamten. On Aug. 30, Cytokinetics presented primary ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The U.S. Food and Drug Administration (FDA) on Thursday extended the Prescription Drug User Fee Act (PDUFA) action date for the New Drug Application (NDA) for Cytokinetics Inc's (NASDAQ:CYTK) ...
Bristol Myers Squibb announced the phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III ...
(RTTNews) - Bristol Myers Squibb (BMY) announced that the Phase 3 ODYSSEY-HCM trial, which evaluated Camzyos or mavacamten for the treatment of adult patients with symptomatic New York Heart ...
In patients with nonobstructive hypertrophic cardiomyopathy (nHCM) treatment with a cardiac myosin inhibitor does not seem to yield significant improvements in quality-of-life (QoL) or oxygen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results